Dr. Reddys Laboratories Ltd.

Dr. Reddy’s Laboratories is currently trading at Rs. 2531.10, up by 7.40 points or 0.29% from its previous closing of Rs. 2523.70 on the BSE.

The scrip opened at Rs. 2530.10 and has touched a high and low of Rs. 2554.90 and Rs. 2521.00 respectively. So far 6930 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2875.00 on 04-Feb-2019 and a 52 week low of Rs. 1888.00 on 21-May-2018.

Last one week high and low of the scrip stood at Rs. 2685.00 and Rs. 2065.30 respectively. The current market cap of the company is Rs. 41908.78 crore.

The promoters holding in the company stood at 26.77%, while Institutions and Non-Institutions held 45.67% and 13.94% respectively.

Dr. Reddy's Laboratories along with its subsidiaries, has re-launched Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of Suboxone (buprenorphine and naloxone) sublingual film, in the United States market.

The re-launch comes on the heels of a favorable decision issued by the United States Court of Appeals for the Federal Circuit concluding that Indivior had not shown that it is likely to succeed on its claim that Dr. Reddy's product infringes US Patent.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.